AbCellera Biologics Inc.
ABCL
$2.33
-$0.06-2.51%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -162.86M | -175.80M | -153.30M | -146.90M | -146.40M |
| Total Depreciation and Amortization | 65.00M | 92.21M | 61.32M | 30.54M | 30.89M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 15.15M | 2.76M | 27.04M | 65.68M | 58.40M |
| Change in Net Operating Assets | -25.84M | -39.34M | -26.45M | 9.16M | 13.23M |
| Cash from Operations | -108.56M | -120.17M | -91.39M | -41.52M | -43.88M |
| Capital Expenditure | -78.40M | -77.20M | -79.01M | -86.10M | -76.95M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 199.81M | 138.58M | 123.91M | 44.51M | -144.16M |
| Cash from Investing | 121.41M | 61.38M | 44.90M | -41.59M | -221.11M |
| Total Debt Issued | 13.50M | 12.63M | 16.09M | 13.71M | 11.59M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.58M | 1.58M | 1.61M | 1.48M | 1.08M |
| Repurchase of Common Stock | -1.58M | -1.08M | -1.08M | -1.08M | -1.08M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -729.00K | -737.00K | -739.00K | -471.00K | -1.23M |
| Cash from Financing | 12.77M | 12.39M | 15.88M | 13.65M | 10.36M |
| Foreign Exchange rate Adjustments | -2.62M | 611.00K | -819.00K | 21.00K | 589.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 23.01M | -45.78M | -31.43M | -69.45M | -254.04M |
